CN111971028A - 用治疗性纳米生物组合物促进训练免疫 - Google Patents

用治疗性纳米生物组合物促进训练免疫 Download PDF

Info

Publication number
CN111971028A
CN111971028A CN201880086231.5A CN201880086231A CN111971028A CN 111971028 A CN111971028 A CN 111971028A CN 201880086231 A CN201880086231 A CN 201880086231A CN 111971028 A CN111971028 A CN 111971028A
Authority
CN
China
Prior art keywords
bone marrow
enhancer
patient
cells
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880086231.5A
Other languages
English (en)
Chinese (zh)
Inventor
W·穆德
J·奥昌多
Z·法亚德
M·内泰亚
L·约斯滕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Radboud Universiteit Nijmegen
Icahn School of Medicine at Mount Sinai
Original Assignee
Stichting Katholieke Universiteit
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Katholieke Universiteit, Icahn School of Medicine at Mount Sinai filed Critical Stichting Katholieke Universiteit
Publication of CN111971028A publication Critical patent/CN111971028A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nuclear Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880086231.5A 2017-11-21 2018-11-20 用治疗性纳米生物组合物促进训练免疫 Pending CN111971028A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762589054P 2017-11-21 2017-11-21
US62/589,054 2017-11-21
PCT/US2018/061935 WO2019103998A2 (en) 2017-11-21 2018-11-20 Promoting trained immunity with therapeutic nanobiologic compositions

Publications (1)

Publication Number Publication Date
CN111971028A true CN111971028A (zh) 2020-11-20

Family

ID=66630773

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880086231.5A Pending CN111971028A (zh) 2017-11-21 2018-11-20 用治疗性纳米生物组合物促进训练免疫

Country Status (7)

Country Link
US (4) US20200261591A1 (https=)
EP (1) EP3713548A4 (https=)
JP (3) JP7330994B2 (https=)
CN (1) CN111971028A (https=)
AU (2) AU2018370828B2 (https=)
CA (1) CA3082830A1 (https=)
WO (1) WO2019103998A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118459539A (zh) * 2021-03-19 2024-08-09 生物治疗探索股份有限公司 用于调节训练免疫的化合物及其使用方法
US12377054B2 (en) 2016-04-29 2025-08-05 Icahn School Of Medicine At Mount Sinai Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230266321A1 (en) * 2020-06-25 2023-08-24 Icahn School Of Medicine At Mount Sinai Live cell engagement assay
IT202100014747A1 (it) * 2021-06-07 2022-12-07 Consiglio Nazionale Ricerche Derivati sterolici come nuovi ligandi del recettore dectina-1 nel trattamento terapeutico di patologie correlate a tale recettore
CA3222851A1 (en) 2021-06-22 2022-12-29 Roy VAN DER MEEL Nucleic acid containing nanoparticles
WO2023192956A2 (en) * 2022-03-31 2023-10-05 Icahn School Of Medicine At Mount Sinai Sphingolipid-loaded nanobiologics for immune regulation
JP2025518282A (ja) 2022-06-03 2025-06-12 バイオ－トリップ ベーフェー 核酸送達のための多価分子に基づく脂質ナノ粒子

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101096386A (zh) * 2007-06-05 2008-01-02 复旦大学 Dectin-1与热休克蛋白Hsp60聚合物及其编码核酸和应用
CN101903018A (zh) * 2007-10-17 2010-12-01 韩国科学技术院 用于递送核酸基因的ldl样阳离子纳米微粒、其制备方法以及使用其递送核酸基因的方法
CN102027019A (zh) * 2007-12-12 2011-04-20 大学健康网络 高密度脂蛋白样肽磷脂支架("hpps")纳米颗粒
CN103118691A (zh) * 2010-08-23 2013-05-22 康干细胞控股有限公司 预防和治疗免疫病变和炎性疾病的包括用nod2激动剂处理的干细胞或其培养物的药物组合物
CN105828834A (zh) * 2013-11-05 2016-08-03 同源生物服务股份有限公司 检查点抑制剂和治疗剂的组合以治疗癌症
WO2016154544A1 (en) * 2015-03-25 2016-09-29 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
WO2017024312A1 (en) * 2015-08-06 2017-02-09 Autotelic Llc Phospholipid-cholesteryl ester nanoformulations and related methods
CN106714836A (zh) * 2015-06-05 2017-05-24 H·李·莫菲特癌症中心研究有限公司 Gm‑csf/cd40l疫苗和检查点抑制剂联合治疗

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10525152B2 (en) * 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101096386A (zh) * 2007-06-05 2008-01-02 复旦大学 Dectin-1与热休克蛋白Hsp60聚合物及其编码核酸和应用
CN101903018A (zh) * 2007-10-17 2010-12-01 韩国科学技术院 用于递送核酸基因的ldl样阳离子纳米微粒、其制备方法以及使用其递送核酸基因的方法
CN102027019A (zh) * 2007-12-12 2011-04-20 大学健康网络 高密度脂蛋白样肽磷脂支架("hpps")纳米颗粒
CN103118691A (zh) * 2010-08-23 2013-05-22 康干细胞控股有限公司 预防和治疗免疫病变和炎性疾病的包括用nod2激动剂处理的干细胞或其培养物的药物组合物
CN105828834A (zh) * 2013-11-05 2016-08-03 同源生物服务股份有限公司 检查点抑制剂和治疗剂的组合以治疗癌症
WO2016154544A1 (en) * 2015-03-25 2016-09-29 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
CN106714836A (zh) * 2015-06-05 2017-05-24 H·李·莫菲特癌症中心研究有限公司 Gm‑csf/cd40l疫苗和检查点抑制剂联合治疗
WO2017024312A1 (en) * 2015-08-06 2017-02-09 Autotelic Llc Phospholipid-cholesteryl ester nanoformulations and related methods

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MIHAI G.NETEA 等: "Trained immunity:A program of innate immune memory in health and disease", 《SCIENCE》 *
张亚历 等: "《大肠癌的基础与临床》", 30 September 1999, 上海科学技术文献出版社 *
张其楷 主编: "《药物设计的基本原理》", 30 April 1990, 中国医药科技出版社 *
马东来 等: "《实用临床免疫学基础》", 30 June 1993, 长春出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12377054B2 (en) 2016-04-29 2025-08-05 Icahn School Of Medicine At Mount Sinai Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
CN118459539A (zh) * 2021-03-19 2024-08-09 生物治疗探索股份有限公司 用于调节训练免疫的化合物及其使用方法

Also Published As

Publication number Publication date
JP7330994B2 (ja) 2023-08-22
JP7772748B2 (ja) 2025-11-18
AU2018370828B2 (en) 2024-11-21
CA3082830A1 (en) 2019-05-31
EP3713548A2 (en) 2020-09-30
AU2018370828A1 (en) 2020-06-04
US20200261591A1 (en) 2020-08-20
WO2019103998A3 (en) 2019-08-22
EP3713548A4 (en) 2021-06-23
US20250268839A1 (en) 2025-08-28
US20200253884A1 (en) 2020-08-13
JP2023145781A (ja) 2023-10-11
US20230355537A1 (en) 2023-11-09
WO2019103998A2 (en) 2019-05-31
JP2021504446A (ja) 2021-02-15
JP2026015394A (ja) 2026-01-29
AU2025201252A1 (en) 2025-03-13

Similar Documents

Publication Publication Date Title
JP7772748B2 (ja) 治療用ナノ生物学的組成物による訓練免疫の促進
KR101866893B1 (ko) Tlr 아고니스트의 치료적 용도 및 병용 요법
JP2024038199A (ja) 細菌由来ミニ細胞を含む組成物およびそれを使用する方法
WO2020092792A2 (en) Method of enhancing immune-based therapy
JP7796707B2 (ja) 治療用ナノバイオロジー組成物での訓練された免疫の阻害
AU2020301417A1 (en) PDL1 positive NK cell cancer treatment
US12337033B2 (en) Encapsulated glycolipid antigens for treatment of neoplastic diseases
CN119486765A (zh) 仿生纳米囊泡和外泌体中管腔局部有效负载的治疗相关生物分子的受控表达
JP2025518126A (ja) がんの治療のための同種異系低免疫生体模倣型ナノ小胞
US20250222102A1 (en) Nk cells expressing il-15 and checkpoint inhibitors for the treatment of cancer
TW202428876A (zh) 治療難治型腦瘤之方法
HK40056270A (en) Encapsulated glycolipid antigens for treatment of neoplastic diseases
HK40045237A (en) Compositions comprising bacterially derived minicells and methods of using the same
KR20190019121A (ko) 종양 내 정맥 형성 촉진제

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination